Panel discussion: bioanalytical considerations for oligonucleotide assessment strategies

What will you learn?

• The bioanalytical considerations for oligonucleotides and their current status within bioanalysis
• How LC−MS, LBA and hybrid approaches are being used to support oligonucleotide assessment strategies and their advantages and drawbacks
• The emerging technologies that could supplement/replace current techniques
• Opportunites for automation and integration of AI/digital tools

Who this may interest?

• Researchers involved in oligonucleotide assessment strategies
• Those working with LC−MS, LBA or hybridization approaches
• Individuals interested in bioanalytical automation and AI/digital tools for oligonucleotides

Speakers

Neil Spooner (Panel discussion Chair)
Director/Co-Founder and Chair
Spooner Bioanalytical Solutions/Patient Centric Sampling Interest Group (PCSIG)

​Neil is the Founder of Spooner Bioanalytical Solutions, helping organizations to develop bioanalytical technologies and workflows and introduce them to the market. He also assists organizations with their understanding of emerging trends in the pharmaceutical industry and bioanalysis. Neil is also the Co-founder and Chair of the PCSIG, a not-for-profit organization that brings together a variety of interested parties who wish to develop and promote the use of patient-centric sampling technologies for blood, plasma, urine and other human matrices, to better facilitate the advancement of human healthcare and well-being. Neil is a Senior Visiting Research Fellow at the University of Hertfordshire (UK), Editor-in-Chief of the journal, Bioanalysis and Chair of the International Reid Bioanalytical Forum. He has published over 70 peer-reviewed manuscripts and delivered over 50 podium presentations.​​​​​​​

Aihua Liu
Executive Director, Bioanalysis
Resolian (PA, USA) 

Dr. Liu holds a Ph.D. in Analytical Chemistry, an M.S. in Pharmaceutical Chemistry, and a B.Sc. in Pharmacy, and brings over two 2 decades of extensive expertise in bioanalysis. Throughout her career, she has held senior leadership positions at several renowned organizations, including Alliance Pharma (Wiltshire, UK), where she served as Senior Director, as well as at Dyad Labs (UT, USA), Covance/LabCorp (NC, USA), and Tandem Labs (UT, USA). Her research and professional efforts focus on the development and validation of innovative bioanalytical methods and sample analysis, with expertise in oligonucleotides, ADCs, proteins, biomarkers, lipids, chiral compounds, small molecules and new modalities. Dr. Liu is deeply engaged within the scientific community and has made significant contributions through her authorship of more than 85 conference posters, oral presentations, and peer-reviewed publications.

Dominic Warrino, PhD
Senior Director of Scientific Services
KCAS Bioanalytical and Biomarker Services (KS, USA)

Dominic Warrino, PhD, is a Senior Director of Scientific Services. His role is to serve as scientific and technical advisor for both clients and internal teams for the development, validation and application of bioanalytical, immunogenicity and biomarker methods for large molecule therapeutics. Dominic joined the company in 2013 and brought with him expertise in a full range of bioanalytical techniques including ECL, ELISA, RIA, flow cytometry, ELISpot, cell-based assays and Luminex. He has 20 years of experience developing and validating immunological assays for biotechnology and pharmaceutical companies. He most recently spent several years in the Biopharma Services department at Viracor-IBT (formally IBT; MO, USA), and previously also worked for Cytogen (formally Cellcor; NJ, USA), Eligix (MA, USA) and Streck Laboratories (NE, USA) developing novel compounds for the treatment of various cancers. Dominic has worked on over 100 large molecule compounds developing and validating PK, PD, ADA and biomarker assays in support of pre-clinical to phase IV testing.

Zamas Lam
SVP and Global Head of Bioanalytical & Preclinical Development for QPS
QPS Holdings, LLC (DE, USA)

Zamas is the Senior Vice President of Preclinical Development at QPS (DE, USA) and is trained in mass spectrometry, carbohydrates and glycoproteins. Zamas is one of the world’s few high-resolution mass spectrometrists by training and by trade, with a passion for biologics mass spectrometry and gene therapy. Since graduate school, he keeps thinking that it will be fun to work on a gene level in drug discovery and development versus at the protein level or at the metabolite level!

Luca Ferarri
Strategy Area Leader for Small Molecule Bioanalytics & Biomarkers
Roche (Basel, Switzerland)

Dr. Luca Ferrari is Strategy Area Leader for small molecule bioanalytics and biomarkers at F. Hoffmann-La Roche, which he joined in 2013. Previously, he spent 17 years at GlaxoSmithKline (Brentford, UK) where he became Head of Bioanalysis at the Italian R&D Site in 2001. In 2010 he joined Aptuit Verona S.r.l. (Italy) as Head of Regulatory Bioanalysis. He possesses an excellent understanding of LC–MS, bioanalytical method development and validation, GxPs and current global bioanalytical guidance. He has previously been a member of the board of Directors of the Italian Society of Chemists (Rome, Italy). He is the author of several scientific papers and a speaker at numerous international conferences.